⌘K
Loading ticker…
As of 2026-08-24, PUMA BIOTECHNOLOGY INC (PBYI) has a 3-month relative strength percentile of 87 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 65. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 5.0%, relative volume 0.85×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
PBYI is in a stage 2 uptrend, week 10. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 11.2% / 32.7%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
PBYI is held by 20 ETFs as of May 2026. Top owner: AVUV at 0.05% weight, $14M notional. Top 3 carry $16M.
Held by 43 ETFs · $47M across latest filings · largest weight 0.72% (ROSC).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| AVUVAvantis U.S. Small Cap Value ETF | 0.05% | $14M | +0.01 pp |
| VTWO | 0.01% | $2M | — |
| AVSC | 0.02% | $685K | — |
| GSSC | 0.04% | $399K | — |
| AVUSAvantis U.S. Equity ETF | 0.00% | $250K | — |
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.05% |
| $246K |
| new |
| VTWV | 0.02% | $237K | — |
| VFMF | 0.02% | $118K | new |
| VFMO | 0.01% | $115K | new |
| EBI | 0.01% | $39K | — |
Showing 10 of 20 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PBYI Jan avg: 3.46% median: 5.10% win: 75% σ: 6.70% n: 4 2022-04-12 → 2026-07-31 | PBYI Feb avg: 8.49% median: 6.82% win: 50% σ: 22.93% n: 4 2022-04-12 → 2026-07-31 | PBYI Mar avg: -9.99% median: -16.05% win: 25% σ: 14.88% n: 4 2022-04-12 → 2026-07-31 | PBYI Apr avg: -1.85% median: -4.34% win: 40% σ: 14.28% n: 5 2022-04-12 → 2026-07-31 | PBYI May avg: -3.65% median: -4.53% win: 40% σ: 19.27% n: 5 2022-04-12 → 2026-07-31 | PBYI Jun avg: 10.93% median: 5.37% win: 80% σ: 22.69% n: 5 2022-04-12 → 2026-07-31 | PBYI Jul avg: 0.76% median: 2.55% win: 60% σ: 7.12% n: 5 2022-04-12 → 2026-07-31 | PBYI Aug avg: 5.88% median: -4.13% win: 50% σ: 39.59% n: 4 2022-04-12 → 2026-07-31 (current) | PBYI Sep avg: -7.94% median: -4.78% win: 50% σ: 14.98% n: 4 2022-04-12 → 2026-07-31 | PBYI Oct avg: -1.67% median: -5.21% win: 25% σ: 9.11% n: 4 2022-04-12 → 2026-07-31 | PBYI Nov avg: 45.96% median: 38.74% win: 75% σ: 47.82% n: 4 2022-04-12 → 2026-07-31 | PBYI Dec avg: 3.10% median: 2.31% win: 50% σ: 13.45% n: 4 2022-04-12 → 2026-07-31 |